Amgen appoints David W. Meline Executive Vice President and Chief Financial Officer
10 June 2014 | By Amgen
Amgen announced the appointment of David W. Meline as executive vice president and chief financial officer, effective July 21, 2014...
List view / Grid view
News
FDA approves expanded label for AZILECT® for treatment across all stages of Parkinson’s Disease
9 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced the U.S. Food and Drug Administration has expanded the indication for AZILECT® (rasagiline tablets)...
Merck to acquire Idenix
9 June 2014 | By Merck
Merck and Idenix Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash...
Giovanni Caforio, M.D., appointed Chief Operating Officer and elected to Board of Directors
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Giovanni Caforio, M.D., has been appointed chief operating officer and elected to Bristol-Myers Squibb’s Board of Directors, effective June 5, 2014. He will continue to report to Lamberto Andreotti, chief executive officer. In addition to his current responsibilities as chief commercial officer, Caforio…
First patient enrolled in new Phase 3 trial program investigating a once-daily dosing regimen of ISENTRESS® (raltegravir)
6 June 2014 | By Merck
Merck announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK...
GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome
6 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the start of a pivotal phase III study, LATITUDE-TIMI 60, to evaluate the effects of losmapimod in patients presenting with acute coronary syndrome...
Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism
6 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that Pradaxa® (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism...
Ranbaxy, Toansa assessment concluded: no risk to public health
5 June 2014 | By The European Medicines Agency
European regulatory authorities have finalised their assessment of reported non-compliance with Good Manufacturing Practice at Ranbaxy Laboratories’ manufacturing site...
Regulatory information – revised guideline on acceptability of names for human medicines is published
4 June 2014 | By The European Medicines Agency
The European Medicines Agency has published a revised guideline on the acceptability of names for human medicines processed through the centralised procedure...
Teva to acquire Labrys Biologics, Inc.: Novel migraine prophylaxis treatment adds significant new dimension to Teva’s growing pain care franchise
4 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva’s array of biotechnology assets and capabilities...
Pivotal Phase III data show polycythemia vera patients on Novartis drug Jakavi® achieved significant improvement in disease control
4 June 2014 | By Novartis
Novartis announced results from the first-ever pivotal Phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera (PV). Jakavi® (ruxolitinib) significantly improved hematocrit control without the need for phlebotomy...
Boehringer Ingelheim announces successful resolution of FDA warning letter
4 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that by a letter dated June 2, the United States Food and Drug Administration has informed the Company about the closure of the Warning Letter...
Ariad announces preliminary safety and efficacy data of ponatinib in patients with newly diagnosed cml from discontinued Phase 3 epic trial
4 June 2014 | By ARIAD Pharmaceuticals Inc
ARIAD Pharmaceuticals, Inc. announced preliminary safety and efficacy data from the discontinued Phase 3 EPIC trial of Iclusig® (ponatinib) vs. imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia...
Additional disclosure regarding the merger between Sun Pharma and Daiichi Sankyo’s subsidiary Ranbaxy
4 June 2014 | By Daiichi Sankyo
As announced in releases dated April 7 and 11, 2014, Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has entered into agreements with Sun Pharmaceutical Industries Ltd. (“Sun Pharma”) in connection with merger of Ranbaxy Laboratories Limited (“Ranbaxy”) into Sun Pharma. Daiichi Sankyo hereby announces additional information regarding the details of this…
HP D300 offers speed and reliability for drug titrations at GSK
3 June 2014 | By kdc communication
GlaxoSmithKline’s quest for improved anti-malarial treatments has been revolutionized by the speed and reliability of the HP D300 Digital Dispenser...
